Wall Street brokerages forecast that Celsion Co. (NASDAQ:CLSN – Get Rating) will report earnings per share of ($1.01) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Celsion’s earnings. The lowest EPS estimate is ($1.05) and the highest is ($0.96). Celsion reported earnings of ($1.35) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 25.2%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Celsion will report full year earnings of ($3.98) per share for the current fiscal year, with EPS estimates ranging from ($4.37) to ($3.52). For the next financial year, analysts anticipate that the firm will report earnings of ($4.18) per share, with EPS estimates ranging from ($4.50) to ($3.76). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Celsion.
A number of equities research analysts recently issued reports on CLSN shares. StockNews.com began coverage on Celsion in a research report on Wednesday. They set a “hold” rating on the stock. HC Wainwright assumed coverage on Celsion in a research report on Wednesday, April 13th. They issued a “buy” rating and a $16.00 price target on the stock.
Hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Celsion during the fourth quarter worth about $55,000. GSA Capital Partners LLP increased its position in Celsion by 435.2% during the 4th quarter. GSA Capital Partners LLP now owns 133,006 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 108,155 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Celsion during the 4th quarter worth approximately $59,000. FNY Investment Advisers LLC bought a new position in Celsion in the 4th quarter valued at approximately $35,000. Finally, Jane Street Group LLC boosted its position in Celsion by 181.8% in the third quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 23,261 shares in the last quarter. 10.75% of the stock is currently owned by hedge funds and other institutional investors.
Celsion Company Profile (Get Rating)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
- Get a free copy of the StockNews.com research report on Celsion (CLSN)
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.